Advertisement

Cancer and Metastasis Reviews

, Volume 2, Issue 4, pp 323–336 | Cite as

Natural killer cells: Artifact to reality:

An odyssey in biology
  • Robert K. Oldham
Article

Summary

The biology of the natural killer cell system is being investigated by many different laboratories using multiple approaches. The rationale for these investigations is the experimental evidence that NK cells play some role in inhibiting tumor growth and metastasis, convey some protective immunity and may be operative in control of differentiation from fetal life to adulthood. Thus, a survey of the literature reveals a multiplicity of studies examining many of these potential roles for NK cells. This review will attempt to summarize some of the findings critical to an understanding of the role NK cells play in immunophysiology and in immune reactions to various diseases. Even after ten years of study, the whole system of ‘natural’ reactivity remains difficult to define. The evidence available would indicate that the NK system while incompletely understood, may be manipulated in favor of the host when threatened by infectous or neoplastic disorders.

Key words

NK cells immunophysiology tumor growth and metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Hellström I, Hellström KE, Pierce GE, Bill AH: Demonstration of cell-bound and humoral immunity against neuroblastoma cells. Proc Nat Acad Sci USA 60: 1231–1238, 1968.Google Scholar
  2. 2.
    Hellström I, Hellström KE, Sjörgen HO, Warner GA: Demonstration of cell-mediated immunity to human neoplasms of various histological types. Int J Cancer 7: 1–16, 1971.Google Scholar
  3. 3.
    Fossati G, Colnaghi MI, Porta GD, Cascinelli N, Veronesi U: Cellular and humoral immunity against human, malignant melanoma. Int J Cancer 8: 344–350, 1971.Google Scholar
  4. 4.
    O'Toole C, Perlmann P, Unsgaard B, Moberger G, Edsmyr F: Cellular immunity to human urinary bladder carcinoma. Part I. Correlation to clinical stage and radiotherapy. Int J Cancer 10: 77–91, 1972.Google Scholar
  5. 5.
    Herberman RB: Cell-mediated immunity to tumor cells. In: Klein G, Weinhouse S (eds) Advances in cancer research, vol 19. Academic Press, New York, 1974. pp 107–263.Google Scholar
  6. 6.
    Herberman RB, Gaylord CE: Conference and workshop on cellular immune reactions to human tumor-associated antigens. Natl Cancer Inst Monogr 37: 1–221, 1973.Google Scholar
  7. 7.
    Rosenberg EB, Herberman RB, Levine PH, Halterman RH, McCoy JL, Wunderlich JR: Lymphocyte cytotoxicity reactions to leukemia-associated antigens in identical twins. Int J Cancer 9: 648–658, 1972.Google Scholar
  8. 8.
    Rosenau W, Moon HD: Lysis of homologous cells by sensitized lymphocytes in tissue culture. J Natl Cancer Inst 27: 471–483, 1961.Google Scholar
  9. 9.
    Oldham RK, Siwarski D, McCoy JL, Plata EJ, Herberman RB: Evaluation of a cell-mediated cytotoxicity assay utilizing 125Iododeoxyuridine-labeled tissue-culture target cells. Natl Cancer Inst Monogr 37: 49–58, 1973.Google Scholar
  10. 10.
    McCoy JL, Herberman RB, Rosenberg EB,Donnelly FC, Levine PH, Alford C: 51Chromium-release assay for cellmediated cytotoxicity of human leukemia and lymphoid tissue-culture cells. Natl CanCer Inst Monogr 37: 59–67, 1973.Google Scholar
  11. 11.
    Byrne M, Heppner G, Stolbach L, Cummings F, McDonough E, Calabresi P: Tumor immunity in melanoma patients as assessed by colony inhibition and microcytotoxicity methods: A preliminary report. Natl Cancer Inst Monogr 37: 3–8, 1973.Google Scholar
  12. 12.
    Sinkovics JG, Tebbi K, Cabiness JR: Cytotoxicity of lymphocytes to established cultures of human tumors: Evidences for specificity. Natl Cancer Inst Monogr 37: 9–18, 1973.Google Scholar
  13. 13.
    McKhann CF, Cleveland PH, Burk MW: Some problems involving in vitro celluar cytotoxicity assays. Natl Cancer Inst Monogr 37: 37–39, 1973.Google Scholar
  14. 14.
    Skurzak H, Steiner L, Klein E, Lamon E: Cytotoxicity of human peripheral lymphocytes for glioma, osteosarcoma, and glia cell lines. Natl Cancer Inst Monogr 37: 93–102.Google Scholar
  15. 15.
    O'Toole C: Standardization of microcytotoxicity assay for cell-mediated immunity. Natl Cancer Inst Monogr 37: 19–24, 1973.Google Scholar
  16. 16.
    Bean MA, Pees H, Rosen G, Oettgen HF: Prelabeling target cells with 3H-proline as a method for studying lymphocyte cytotoxicity. Natl Cancer Inst Monogr 3: 41–48, 1973.Google Scholar
  17. 17.
    Takasugi M, Mickey MR, Terasaki PI: Quantitation of the microassay for cell-mediated immunity through electronic image analysis. Natl Cancer Inst Monogr 37: 77–84, 1973.Google Scholar
  18. 18.
    Takasugi M, Mickey MR, Terasaki PI: Reactivity of lymphocytes from normal persons on cultured tumor cells. Cancer Res 33: 2898–2902, 1973.Google Scholar
  19. 19.
    Herberman RB, Nunn ME, Lavrin DH, Asofsky R: Effect of antibody to o antigen on cell-mediated immunity induced in syngeneic mice by murine sarcoma virus. J Natl Cancer Inst 51: 1509–1512, 1973.Google Scholar
  20. 20.
    Oldham RK, Herberman RB: Evaluation of cell-mediated cytotoxic reactivity aganist tumor associated antigens with 125I-Iododeoxyuridine labeled target cells. J Immunol 111: 1862–1871, 1973.Google Scholar
  21. 21.
    leMevel BP, Oldham RK, Wells SA, Herberman RB: An evaluation of 125I-Iododeoxyuridine as a cellular label for in vitro assays: Kinetics of incorporation and toxicity. J Natl Cancer Inst 51: 1551–1558, 1973.Google Scholar
  22. 22.
    Takasugi M, Mickey MR, Terasaki PI: Studies on specificity of cell-mediated immunity to human tumors. J Natl Cancer Inst 53: 1527–1538, 1974.Google Scholar
  23. 23.
    DeVries JE, Cornain S, Rümke P: Cytotoxicity of non-T versus T-lymphocytes from melanoma patients and healthy donors on short-and long-term cultured melanoma cells. Int J Cancer 14: 427–434, 1974.Google Scholar
  24. 24.
    Herberman RB, Aoki T, Nunn M, Lavrin DH, Soares N, Gazdar A, Holden H, Chang KSS: Specificity of 51Cr-release cytotoxicity of lymphocytes immune to murine sarcoma virus. J Natl Cancer Inst 53: 1103–1111, 1974.Google Scholar
  25. 25.
    Kiessling R, Klein E, Wigzell H: ‘Natural’ killer cells in the mouse. I. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Specificity and destruction according to genotype. Eur J Immunol 5: 112–117, 1975.Google Scholar
  26. 26.
    Herberman RB, Nunn ME, Lavrin DH: Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. I. Distribution of reactivity and specificity. Int J Cancer 16: 216–229, 1975.Google Scholar
  27. 27.
    Kiessling R, Klein E, Pross H, Wigzell H: ‘Natural’ killer cells in the mouse. Part II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell. Eur J Immunol 5: 117–122, 1975.Google Scholar
  28. 28.
    Herberman RB, Nunn ME, Holden HT, Lavrin DH: Natural cytotoxic reactivity of mouse lymphoid cells against synge-Neic and allogeneic tumors. II. Characterization of effector cells. Int J Cancer 16: 230–239, 1975.Google Scholar
  29. 29.
    Oldham RK, Djeu JY, Cannon GB, Siwarski D, Herberman RB: Cellular microcytotoxicity in human tumor systems: Analysis of results. J Natl Cancer Inst 55: 1305–1318, 1975.Google Scholar
  30. 30.
    Oldham RK, Weiner RS, Mathe G, Breard J, Simmler MC, Carde P, Herberman RB: Cell-mediated immune responsiveness of patients with acute lymphocytic leukemia in remission. Int J Cancer 17: 326–337, 1976.Google Scholar
  31. 31.
    Pross HF, Jondal M: Cytotoxic lymphocytes from normal donars. A functional marker of human non-T lymphocytes. Clin Exp Immunol 21: 226–235, 1975.Google Scholar
  32. 32.
    Pross HF, Baines MG: Characteristics of human natural killer cells. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York, 1980, pp 151–159.Google Scholar
  33. 33.
    Herberman RB: Introduction. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York, 1980, pp 1–6.Google Scholar
  34. 34.
    Herberman RB (ed): Natural cell-mediated immunity against tumors. Academic Press, New York, 1980.Google Scholar
  35. 35.
    Herberman RB, Holden HT: Natural cell-mediated immunity. Adv Cancer Res 27: 305–377, 1978.Google Scholar
  36. 36.
    Oldham RK, Ortaldo JR, Holden HT, Herberman RB: Direct comparison of three isotopic release microtoxicity assays as measures of cell-mediated immunity to Gross Virusinduced lymphomas in rats. J Natl Cancer Inst 58: 1061–1067, 1977.Google Scholar
  37. 37.
    Oldham RK, Ortaldo JR, Herberman RB: Natural cytotoxic reactivity of rat lymphocytes against Gross virus-induced tumor cell lines as measured by [125I]Iododeoxyuridine and tritiated proline microcytotoxicity assays. Cancer Res 37: 4467–4474, 1977.Google Scholar
  38. 38.
    Herberman RB, Oldham RK: Editorial. Problems associated with study of cell-mediated immunity to human tumors by microcytotoxicity assays. J Natl Cancer Inst 55: 749–753, 1975.Google Scholar
  39. 39.
    Golub SH, Golightly MG, Zielske JV: ‘NK-like’ cytotoxicity of human lymphocytes cultured in media containing fetal bovine serum. Int J Cancer 24: 273–283, 1979.Google Scholar
  40. 40.
    Haller O: Mouse natural cell-mediated cytotoxicity to human leukemia: Independence of serum source used for target-cell culturing and cytotoxicity asay. J Natl Cancer Inst 60: 1433–1438, 1978.Google Scholar
  41. 41.
    Hanna N, Davis TW, Fidler IJ: Environmental and genetic factors determine the level of NK activity of nude mice and affect their suitability as models for experimental nutation. Int J Cancer 30: 371–376, 1982.Google Scholar
  42. 42.
    Holden HT, Oldham RK, Ortaldo JR, Herberman RB: Cyropreservation of the functional reactivity of normal and immune leukocytes and of tumor cells. In: Bloom BR, David JR (eds) In vitro methods in cell-mediated and tumor immunity. Academic Press, New York, 1976, pp 723–729.Google Scholar
  43. 43.
    Holden HT, Oldham RK, Ortaldo JR, Herberman RB: Standardization of chromium-51 release, cell-mediated cytotoxicity assay: Cryopreservation of mouse effector and target cells. J Natl Cancer Inst 58: 611–622, 1977.Google Scholar
  44. 44.
    Oldham RK, Dean JH, Cannon GB, Graw R, Dunston G, Applebaum F, McCoy J, Herberman RB: Cryopreservation of human lymphocyte function as measured by in vitro assays. Int J Cancer 18: 145–155, 1976.Google Scholar
  45. 45.
    Herberman RB, Oldham RK, Connor RJ: Statistical analysis and selection of baseline controls in cytotoxicity assay. In: Bloom BR, David JR (eds) In vitro methods in cell-mediated and tumor immunity. Academic Press, New York, 1976, pp 481–488.Google Scholar
  46. 46.
    Oldham RK, Gail MH, Baker MA, Forbes JT, Heineman W, Hersch E, Holmes EC, Ritts RE, Wright PW: Immunological studies in a double blind randomized trial comparing intrapleural BCG against placebo in patients with resected stage I non-small cell lung cancer. Cancer Immunol Immunother 13: 164–173, 1982.Google Scholar
  47. 47.
    Herberman RB, Djeu JY, Kay HD, Ortaldo JR, Riccardi C, Bonnard GD, Holden HT, Fagnani R, Santoni A, Puccetti P: Natural killer cells: Characteristics and regulation of activity. Immunol Rev 44: 43–70, 1979.Google Scholar
  48. 48.
    Mattes MJ, Sharrow SO, Herberman RB, Holden HT: Identification and separation of Thy-I positive mouse spleen cells active in natural cytotoxicity and antibody-dependent cellmediated cytotoxicity. J Immunol 123: 2851–2860, 1979.Google Scholar
  49. 49.
    Koo GC, Jacobson JB, Hammerling GJ, Hammerling U: Antigenic profile of murine natural killer cells. J Immunol 125: 1003–1006, 1980.Google Scholar
  50. 50.
    Seaman WE, Talal N, Herzenberg LA, Ledbetter JA: Surface antigens on mouse natural killer cells: Use of monoclonal antibodies to inhibit or to enrich cytotoxic activity. J Immunol 127: 982–986, 1981.Google Scholar
  51. 51.
    West WH, Cannon GB, Kay HD, Bonnard GD, Herberman RB: Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: Characterization of effector cells. J Immunol 118: 355–361, 1977.Google Scholar
  52. 52.
    Kaplan J, Callewaert DM: Expression of human T-lymphocyte antigens by natural killer cells. J Natl Cancer Inst 60: 961–964, 1978.Google Scholar
  53. 53.
    Eremin O, Coombs RRA, Plumb D, Ashby J: Characterization of the human natural killer (NK) cell in blood and lympoid organs. Int J Cancer 21: 42–50, 1978.Google Scholar
  54. 54.
    Fast LD, Hansen JA, Newman W: Evidence for T cell nature and heterogeneity within natural killer (NK) and antibody-dependent cellular cytotoxicity (ADCC) effectors: A comparison with cytolytic T lymphocytes (CTL). J Immunol 127: 448–452, 1981.Google Scholar
  55. 55.
    Abo T. Balch CM: A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol 127: 1024–1029, 1981.Google Scholar
  56. 56.
    Nieminen P, Paasivuo R, Saksela E: Effect of a monoclonal anti-large granular lymphocyte antibody on the human NK activity. J Immunol 128: 1097–1101, 1982.Google Scholar
  57. 57.
    Kay HD, Horwitz DA: Evidence by reactivity with hybridoma antibodies for a possible myeloid origin of peripheral blood cells active in natural cytotoxicity and antibodydependent cell-mediated cytotoxicity. J Clin Invest 66: 847–852, 1980.Google Scholar
  58. 58.
    Zarling JM, Kung PC: Monoclonal antibodies which distinguish between human NK cells and cytotoxic T lymphocytes. Nature 288: 394–396, 1980.Google Scholar
  59. 59.
    Ortaldo JR, Sharrow SO, Timonen T, Herberman RB: Determination of surface antigens on highly purified human NK cells by flow cytometry with monoclonal antibodies. J Immunol 127: 2401–2404, 1981.Google Scholar
  60. 60.
    Breard J, Reinherz EI, O'Brien D, Schlossman SF: Delineation of an effector population responsible for natural killing and antibody dependent cellular cytotoxicity in man. Clin Immunol Immunopathol 17: 145–151, 1980.Google Scholar
  61. 61.
    Breard J, Reinherz EI, Kung PC, Goldstein G, Schlossman SF: A monoclonal antibody reactive with human peripheral blood monoctyes and natural killer cells. J Immunol 126: 359–364, 1981.Google Scholar
  62. 62.
    Zarling JF, Kung PC: Monoclonal antibodies which distinguish between human NK and cytotoxic T lymphocytes. Nature 288: 394–396, 1980.Google Scholar
  63. 63.
    Todd RF, Nadler LM, Schlossman SF: Antigens on human monocytes identified by monoclonal antibodies. J Immunol 126: 1435–1442, 1981.Google Scholar
  64. 64.
    Keller R: Macrophage-mediated natural cytotoxicity against various target cells in vitro. I. Comparison of tissue macrophages from diverse anatomic sites and from different strains of rats and mice. Br J Cancer 37: 732–741, 1978.Google Scholar
  65. 65.
    Mantovani A, Jerrells TR, Dean JH, Herberman RB: Cytolytic and cytostatic activity on tumor cells of circulating human monocytes. Int J Cancer 23: 18–27, 1979.Google Scholar
  66. 66.
    Tagliabue A, Mantovani A, Kilgallen M, Herberman RB, McCoy JL: Natural cytotoxicity of mouse monocytes and macrophages. J Immunol 122: 2363–2370, 1979.Google Scholar
  67. 67.
    Fidler IJ, Davis TW, Raz A: The influence of host health and environment on natural cytotoxicity of mouse macrophages. Cancer Immunol Immunother 11: 195–199, 1981.Google Scholar
  68. 68.
    Timonem T, Ortaldo JR, Herberman RB: Characteristics of human large granular lymphocytes and relationship to NK and K cells. J Exp Med 153: 569, 1981.Google Scholar
  69. 69.
    Herberman RB, Ortaldo JR: Natural killer cells: Their role in defenses against disease. Science 214: 24–30, 1981.Google Scholar
  70. 70.
    Herberman RB: Natural killer cells. Hosp Prac 17: 93–103, 1982.Google Scholar
  71. 71.
    Ortaldo JR: Natural killer cells: A separate lineage? In: Herberman RB (ed) NK cells and other natural effector cells. Academic Press, New York, 1982, pp 265–271.Google Scholar
  72. 72.
    Babior BM, Parkinson DW: The NK cell: A phagocyte in lymphocyte's clothing? Nature 298: 511–573, 1982.Google Scholar
  73. 73.
    Timonen T, Ortaldo JR, Vose BM, Henkart M, Alvarez, Herberman RB: Cultures of human natural killer cells (large granular lymphocytes) and T cells in the presence of interleukin-2-containing conditioned medium. J Reticuloendothel Soc 33: 67–80, 1983.Google Scholar
  74. 74.
    Ortaldo JR, Klein R, Allavena P: Phenotypic studies of NK progenitors and clones (Abstract). 5th Int Cong Immunol (in press).Google Scholar
  75. 75.
    Allavena P, Klein R, Ortaldo JR: Characteristics of human NK clones: Study of specificity and phenotype (Abstract). 5th Int Cong Immunol (in press).Google Scholar
  76. 76.
    Ortaldo JR, Oldham RK, Cannon GB, Herberman RB: Specificity of natural cytotoxic reactivity of normal human lymphocytes against a myeloid leukemia cell line. J Natl Cancer Inst 59: 77–82, 1977.Google Scholar
  77. 77.
    Takasugi M, Mickey MR, Terasaki PI: Studies on specificity of cell-mediated immunity to human tumors. J Natl Cancer Inst 53: 1527–1538, 1974.Google Scholar
  78. 78.
    Takasugi M, Mickey MR: Interaction analysis of selective and nonselective cell-mediated cytotoxicity. J Natl Cancer Inst 57: 255–261, 1976.Google Scholar
  79. 79.
    Takasugi M, Koide Y, Akira D, Ramseyer A: Specificities in natural cell-mediated cytotoxicity by the cross-competition assay. Int J Cancer 19: 291–297, 1977.Google Scholar
  80. 80.
    Takasugi M, Akira D, Takasugi J, Mickey MR: Specificities in human cell-mediated cytotoxicity. J Natl Cancer Inst 59: 69–75, 1977.Google Scholar
  81. 81.
    Herberman RB, Ortaldo JR. Specificity of NK cells. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York 1980, pp 873–882.Google Scholar
  82. 82.
    Phillips WH, Ortaldo JR, Herberman RB: Selective depletion of human natural killer cells on monolayers of target cells. J Immunol 125: 2332–2327, 1980.Google Scholar
  83. 83.
    Forbes JT, Oldham RK: Kinetic analysis of specificity in human natural cell-mediated cytotoxicity. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York, 1980, pp 819–834.Google Scholar
  84. 84.
    Jensen PJ, Koren HS: Heterogeneity in natural killing. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York, 1980, pp 883–892.Google Scholar
  85. 85.
    Jensen PJ, Koren HS: Depletion of NK by celular immunoadsorption. J Immunol 123: 1127–1132, 1979.Google Scholar
  86. 86.
    Hansson M, Karre K, Baas T, Kiessling R, Klein G: Intra-and interspecies reactivity of human and mouse natural killer (NK) cells. J ImMunol 121: 6–12, 1979.Google Scholar
  87. 87.
    Lynch DH, DeWitt CW: Analysis of cytotoxic effector cell populations by kinetic and monolayer adsorption techniques. J Immunol 124: 222–226, 1980.Google Scholar
  88. 88.
    Callewaert DM, Kaplan J, Johnson DF, Peterson WDJr: Spontaneous cytotoxicity of cultured human cell lines mediated by normal peripheral blood lymphocytes. II. Specificity for target antigens. Cell Immunol 42: 103–112, 1979.Google Scholar
  89. 89.
    Stutman O, Dien P, Wisun RE, Lattime EC: Natural cytotoxic cells against solid tumors in mice: Blocking of cytotoxicity by D-mannose. Proc Nat Acad Sci USA (77): 2895–2898, 1980.Google Scholar
  90. 90.
    Forbes JT, Bretthauer RK, Oeltmann TN: Mannose 6-, fructose 1-, and fructose 6-phosphates inhibit human natural cell-mediated cytotoxicity. Proc Nat Acad Sci USA 78: 5797–5801, 1981.Google Scholar
  91. 91.
    Urdal DL, Kawase I, Henney CS: NK cell-target interactions: approaches towards definition of recognition structures. Cancer Met Rev 1: 65–82, 1982.Google Scholar
  92. 92.
    Newman W: Selective blockage of human natural killer cells by a monoclonal antibody. Proc Nat Acad Sci USA 79: 3858–3862, 1982.Google Scholar
  93. 93.
    Schmidt A, Ortaldo JR, Herberman RB: Inhibition of human natural cell reactivity by exogenous adenosine 5'-triphosphate. Duke University Workshop on Natural Killer Cells, 1982.Google Scholar
  94. 94.
    Grossman Z, Herberman RB: Hypothesis on the development of natural killer cells and their relationship to T cells. In: Herberman RB (ed) NK cells and other natural effector cells. Academic Press, New York, 1982, pp 229–238.Google Scholar
  95. 95.
    Koide Y, Kwok R, Takasugi M: Studies of effector cell, antibody, and target cell interactions in natural cel-mediated cytotoxicity. Int J Cancer 22: 546–551, 1978.Google Scholar
  96. 96.
    Koide Y, Takasugi M: Determination of specificity in natural ceL1-mediated cytotoxicity by natural antibodies. J Natl Cancer Inst 59: 1099–1105, 1977.Google Scholar
  97. 97.
    Akira D, Takasugi M: Loss of specific natural cel-mediated cytotoxicity with absorption of natural antibodies from serum. Int J Cancer 19: 747–755, 1977.Google Scholar
  98. 98.
    Pross HF, Luk SS, Baines MG: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. V. The role of serum-derived heterologous membrane antigens. Int J Cancer 21: 291–298, 1978.Google Scholar
  99. 99.
    Henney CS, Ortaldo J: NK Cell Workshop report. In: Vitetta ES (ed) NK cells workshop Report, UCLA Symposium on Molecular and Cellular Biology, vol XXIV. Academic Press, New York, 1982, pp 535–537.Google Scholar
  100. 100.
    Andersson LC, Nilsson K, Gahmberg CG: K562-A human erythroleukemic cell lines. Int J Cancer 23: 143–147, 1979.Google Scholar
  101. 101.
    Lozzio BB, Lozzio CB, Bamberger EG, Feliv AS: A multipotential leukemia cell line (K-562) of human orogin. Proc Soc Exp Biol Med 166: 546–550, 1981.Google Scholar
  102. 102.
    Gidlund M, Örn A, Pattengale PK, Jansson M, Wigzell H, Nilsson K: Natural killer cells kill tumour cells at a given stage of differentiation. Nature 292: 848–850, 1981.Google Scholar
  103. 103.
    Dokhelar MC, Testa V, Vainchenker W, Finale Y, Tetaud C, Salem P, Tursz T: NK Cell sensitivity of the leukemia K562 cells: Effect of sodium butyrate and hemin induction. J Immunol 128: 211–215, 1982.Google Scholar
  104. 104.
    Werkmeister J, Helfland SL, Haliotis T, Rubin P, Pross H, Roder J: Tumor cell differentiation modulates susceptibility to natural killer cells. Cell Immunol 69: 122–127, 1982.Google Scholar
  105. 105.
    Sutherland R, Delia D, Schneider C, Newman R, Kemshead J, Greaves M: Ubiquitous cell-surface glycoprotein on tumor cells is proliferation associated receptor for transferrin. Proc Natl Acad Sci USA 78: 4515–4519, 1981.Google Scholar
  106. 106.
    Trowbridge IS, Omary MB: Human cell surface glycoprotein related to cell proliferation is the receptor for transferrin. Proc Natl Acad Sci USA 78: 3039–3043, 1981.Google Scholar
  107. 107.
    Enns CA, Shindelman J, Tonik JE, Sussman H: Radioimmunochemical measurement of the transferrin receptor in human trophoblast and reticulocyte membranes with a specific antireceptor antibody. Proc Natl Acad Sci 78: 4222–4225, 1981.Google Scholar
  108. 108.
    Nunn ME, Herberman RB, Holden HT: Natural cellmediated cytotoxicity in mice against non-lymphoid tumor cells and some normal cells. Int J Cancer 20: 381–387, 1977.Google Scholar
  109. 109.
    Hansson M, Kärre K, Kiessling R, Roder J, Andersson B, Hayry P: Natural NK-cell targets in the mouse thymus: Characteristics of the sensitive cell population. J Immunol 123: 765–771, 1979.Google Scholar
  110. 110.
    Durdik JM, Beck BN, Clark EA, Henney CS: Characterization of a lymphoma cell variant selectively resistant to natural killer cells. J Immunol 125: 683–688, 1980.Google Scholar
  111. 111.
    Hanna N: Role of natural killer cells in control of cancer metastasis. Cancer Met Rev 1: 45–64, 1982.Google Scholar
  112. 112.
    Clark EA, Engel D, Windsor NT: Immune responsiveness of SM/J mice: Hyper NK Cell activity mediated by NK 1+ Qa 5- cells. J Immunol 127: 2391–2395, 1981.Google Scholar
  113. 113.
    Storer JB: Longevity and gross pathology at death in 22 inbred strains of mice. J Gerontol 21: 404, 1966.Google Scholar
  114. 114.
    Gorelik E, Herberman RB: Susceptibility of various strains of mice to urethane-induced lung tumors and depressed natural killer cell activity. J Natl Cancer Inst 67: 1317–1322, 1981.Google Scholar
  115. 115.
    Gorelik E, Herberman RB: Inhibition of the activity of mouse NK cells by urethane. J Natl Cancer Inst 66: 543–548, 1981.Google Scholar
  116. 116.
    Gorelik E, Wiltrout R, Okumara K, Habu S, Herberman RB: Acceleration od metastatic growth in anti-asialo GM1-treated mice. In: Herberman RB (ed) NK cells and other natural effector cells. Academic Press, New York, 1982, pp 1331–1377.Google Scholar
  117. 117.
    Hanna N, Fidler IJ: Relationship between metastatic potential and rersistance to natural killer cell-mediated cytotoxicity in three murine tumor systems. J Natl Cancer Inst 66: 1183–1190, 1981.Google Scholar
  118. 118.
    Gorelik E, Herberman RB: Depression of natural antitumor resistance of C57BL/6 mice by leukemogenic doses of radiation and restoration of resistance by transfer of bone marrow or spleen cells from normal, but not beige, syngeneic mice. J Natl Cancer Inst 69: 89–93, 1982.Google Scholar
  119. 119.
    Hanna N, Burton RC: Definitive evidence that natural killer (NK) cells inhibit experimental tumor metastasis in vivo. J Immunol 127: 1754–1758, 1981.Google Scholar
  120. 120.
    Rosenberg EB, McCoy JL, Green SS, Donelly FC, Siwarski D, Levine PH, Herberman R: Destruction of human lymphoid tissue-culture cell lines by human peripheral lymphocytes in 51Cr-release cellular cytotoxicity assays. J Natl Cancer Inst 52: 345–352, 1974.Google Scholar
  121. 121.
    Forbes JT, Niblack GD, Fuchs R, Richie RE, Johnson HK, Oldham RK: Human natural cell-mediated cytotoxicity. I. Levels in peripheral blood, cord blood, and thoracic duct lymphocytes. Cancer Immunol Immunother 11: 139–145, 1981.Google Scholar
  122. 122.
    Nagel JE, Collins GD, Adler WH: Spontaneaous or natural killer cytotoxicity of K562 erythroleukemic cells in normal patients. Cancer Res 41: 2284–2288, 1981.Google Scholar
  123. 123.
    Roder JC, Pross HF: The biology of the human natural killer cell. J Clin Immunol 2 249–263, 1982.Google Scholar
  124. 124.
    Toivanen P, Uksila J, Leino A, Lassila O, Hirvonen T, Ruuskanen O: Development of mitogen responding T cells and natural killer cells in the human fetus. Immunol Rev 57: 89–105, 1981.Google Scholar
  125. 125.
    Haller O, Kiessling R, Orn A, Wigzell H: Generation of natural killer cells: An autonomous function of the bone marrow. J Exp Ned 145: 1411–1416, 1977.Google Scholar
  126. 126.
    Baines MG, Pross HF, Millar KG: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. IV. The suppressive effect of normal pregnancy. Am J Obstet Gynecol 130: 741–744, 1978.Google Scholar
  127. 127.
    Uksila J, Olli L, Hirvonen T, Toivanen P: Development of natural killer cell function in the human fetus. J Immunol 130: 153–156, 1983.Google Scholar
  128. 128.
    Kaplan J, Shofe TC, Bollinger RO, Smith J: Human newborns are deficient in natural killer activity. J Clin Immunol 2: 350–355, 1982.Google Scholar
  129. 129.
    Forbes JT, Greco FA, Oldham RK: Natural cell-mediated cytotoxicity II. Levels in neoplastic disease. Cancer Immunol Immunother 11: 147–153, 1981.Google Scholar
  130. 130.
    McCoy J, Herberman R, Perlin E, Levine P, Alford C: 51Cr release cellular lymphocyte cytotoxicity as a possible measure of immunological competence of cancer patients. Proc Am Assoc Cancer Res 14: 107, 1973.Google Scholar
  131. 131.
    Pross HF, Baines MG: Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. I. The effect of malignant disease. Int J Cancer 18: 593–604, 1976.Google Scholar
  132. 132.
    Pross HF, Baines MG: Natural Killer cells in tumor-bearing patients. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York, 1980, pp 1063–1072.Google Scholar
  133. 133.
    Takasugi M, Ramseyer A, Takasugi J: Decline of natural nonselective cell-mediated cytotoxicity in patients with tumor progression. Cancer Res 37: 413–418, 1977.Google Scholar
  134. 134.
    Eremin O, Ashby J, Stephens JP: Human natural cytotoxicity in the blood and lymphoid organs of healthy donors and patients with malignant disease. Int J Cancer 21: 35–41, 1978.Google Scholar
  135. 135.
    Koren HS, Amos DB, Buckley RH: Natural killing in immunodeficient patients. J Immunol 120: 796–799, 1978.Google Scholar
  136. 136.
    Drew WL, Miner RC, Zielgler JL: Cytomegalovirus and Kaposi's sarcoma in young homosexual men. Lancet 8290: 125–127, 1982.Google Scholar
  137. 137.
    Report of the centers for disease control task force on Kaposi's sarcoma and opportunistic infections. Special report: Epidemiologic aspects of the current outbreak of Kaposis's sarcoma and opportunistic infections. N Engl J Med 306: 248–252, 1982.Google Scholar
  138. 138.
    Krown SE, Real FX, Cunningham, Rundles S, Myskowski PL, Koziner B, Fein S, Mittleman A, Oettgen HF, Safai B: Recombianant leukocyte A interferon in homosexual men with Kaposi's sarcoma. N Engl J Med 309: 923–924, 1983.Google Scholar
  139. 139.
    Oehler JR Herberman RB: Natural cell-mediated cytotoxicity in rats. III. Effects of immunopharmacologic treatments on natural reactivity and on reactivity augmented by polyinosinic-polycytidylic acid. Int J Cancer 21: 221–229, 1978.Google Scholar
  140. 140.
    Djeu JY, Heinbaugh JA, Holden HT, Herberman RB: Augmentation of mouse natural killer cell activity by interferon and interferon inducers. J Immunol 122: 175–181, 1979.Google Scholar
  141. 141.
    Herberman RB, Ortaldo JR, Bonnard GD: Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature 277: 221–223, 1979.Google Scholar
  142. 142.
    Senik A, Gresser I, Maury C, Gidlund M, Orn A, Wigzell H: Enhancement by interferon of natural killer cell activity in mice. Cell Immunol 44: 186–200, 1979.Google Scholar
  143. 143.
    Zarling JM, Eskra L, Borden EC, Horoszewicz J, Carter WA. Activation of human natural killer cells cytotoxic for human leukemia cells by purified interferon. J Immunol 123: 63–70, 1979.Google Scholar
  144. 144.
    Silva A, Bonavida B, Targan S: Mode of action of interferon-mediated modulation of natural killer cytotoxic activity: Recruitment of pre-NK cells and enhanced kinetics of lysis. J Immunol 125: 479–484, 1980.Google Scholar
  145. 145.
    deLandazuri MO, López-Botet M, Timonen T, Ortaldo JR, herberman RB: Human large granular lymphocytes: Spontaneous and interferon-boosted NK activity against adherent and nonadherent tumor cell lines. J Immunol 127: 1380–1383, 1981.Google Scholar
  146. 146.
    Lotzová E, Savary CA, Gutterman JU, Hersh EM: Modulation of natural killer cel-mediated cytotoxicity by partially purified and cloned interferon-α. Cancer Res 42: 2480–2488, 1982.Google Scholar
  147. 147.
    Kadish AS, Doyle AT, Steinhauer EH, Ghossein NA: Natural cytotoxicity and interferon production in human cancer: Deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol 127: 1817–1822, 1981.Google Scholar
  148. 148.
    Sherwin S, Fein S, Whisnant J, Oldham R: Phase I trials of recombinant and nonrecombinant alpha interferons in cancer patients. In: Merigan TC, Friedman RM (eds) Interferons UCLA Symposia on Molecular and Cellular Biology, Vol XXV. Academic Press, New York, 1982, pp 433–447.Google Scholar
  149. 149.
    Maluish AE, Conlon J, Ortaldo JR, Sherwin SA, Leavitt R, Fein S, Weirnitz P, Oldham RK, Herberman RB: Modulation of NK and monocyte activity in advanced cancer patients receiving interferon. In: Merigan TC, Friedman RM (eds) Interferons UCLA Symposia on Molecular and Cellular Biology, Vol XXV. Academic Press, New York, 1982, pp. 377–386.Google Scholar
  150. 150.
    Einhorn S: Enhancement of human NK activity by interferon. In vivo and in vitro studies. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York, 1980, pp. 529–536.Google Scholar
  151. 151.
    Laszlo J, Huang A, Bernckman W, Koren H, Cianciolo G, Buckley CEJr, Cox E, Cashdollar E, Metzgar R, Lucas VSJr, Jepp C, Dorenkamp S: Immunopharmacology of human lymphoblastoid interferon (IF) in man (Abstract). Proc Am Assoc Cancer Res 23: 245, 1982.Google Scholar
  152. 152.
    Bash JF, Teitelbaum D, Sreevalsan T, Neefe JR: Immunomodulatory activities of human leukocyte interferon in advanced cancer patients. J Biol Resp MOd 2: 57–65, 1983.Google Scholar
  153. 153.
    Reid LM, Minato N, Gressor I, Holland J, Kadish A, Bloom BR: Influence of anti-mouse interferon serum on the growth and metastasis of tumor cells persistently infected with virus and of human prostatic tumors in athymic nude mice. Proc Nat Acad Sci USA 78: 1171–1175, 1981.Google Scholar
  154. 154.
    Dennert G: Cloned lines of natural killer cells. Nature 287: 47–49, 1980.Google Scholar
  155. 155.
    Nabel G, Bucalo LR, Allard J, Wigzell H, Cantor H: Multiple activities of a cloned cell line mediating natural killer cell function. J Exp Med 153: 1582–1591, 1981.Google Scholar
  156. 156.
    Kedar E, Ikejiri BL, Sredni B, Bonavida B, Herberman RB: Propagation of mouse cytotoxic clones with characteristics of natural killer (NK) cells. Cell Immunol 69: 305–329, 1982.Google Scholar
  157. 157.
    Ortaldo JR, Timonen TT: Analysis of fresh human NK cells and their IL-2 maintained cultures: Comparison with other lymphoid populations. In: Serrou B, Rosenfeld C, Daniels JC, Saunders JP (eds) Current concepts in human immunology and cancer immunomoduation. Elsevier/North Holland Biomedical Press, Amsterdam, 1982, pp 273–281.Google Scholar
  158. 158.
    Timonen T, Ortaldo JR, Stadler BM, Bonnard GD, Sharrow SO, Herberman RB: Cultures of purified human natural killer cells: Growth in the presence of Interleukin 2. Cell Immunol 72: 178–185, 1982.Google Scholar
  159. 159.
    Grimm EA, Mazumder A, Zhang HZ, Rosenberg SA: Lymphokine-activated killer cell phenomenon: Lysis of natural killer-resistant fresh solid tumor cells by Interleukin-2 activated autologous human peripheral blood lymphocytes. J Exp Med 155: 1823–1841, 1982.Google Scholar
  160. 160.
    Oldham RK, Simmler MC: Possible role of lymphocyte cytotoxicity in bobe-marrow grafting. Transplant Proc 6: 417–419, 1974.Google Scholar
  161. 161.
    Lopez C, Kirkpatrick D, Sorrell M, O'Reilly RJ, Ching C: Association between pre-transplant natural kill and graft versus host disease after stem cell transplantation. Lancet (ii): 1103–1107, 1979.Google Scholar
  162. 162.
    Livnat S, Seigneuret M, Storb R, Prentice RL: Analysis of cytotoxic effector cell function in patients with leukaemia or aplastic anaemia before and after bone marrow transplantation. J Immunol 124: 481–490, 1980.Google Scholar
  163. 163.
    Lopez C, Kirkpatrick D, Livnat S, Storb R: Letter to the editor: Natural killer cells in bone marrow transplantation. Lancet 2: 1025, 1980.Google Scholar
  164. 164.
    Roder JD, Haliotis T, Klein M, Korec S, Jett J, Ortaldo J, Herberman RB, Katz P, Fauci AS: A new immunodeficiency disorder in humans involving NK Cells. Nature 284: 553–555, 1980.Google Scholar
  165. 165.
    Haliotis T, Roder JC, Klein M, Ortaldo J, Fauci AS, Herberman RB: Chediak-Higashi gene in humans. I. Impairmen of natural killer function. J Exp Med 151: 1029–1058, 1980.Google Scholar
  166. 166.
    Klein M, Roder J, Haliotis T, Koree S, Jett J, Herberman RB, Katz P, Fauci AS: Chediak-Higashi gene in humans. II. the selectivity of the defect in natural-killer and antibody dependend cell-mediated cytotoxicity function. J Exp Med 151: 1049–1058, 1980.Google Scholar
  167. 167.
    Virelizer JL, Lagru A, Durandy A, Arenzaan F, Oury C, Griscelli C, Reinert P: Letter to the editor: Reversal of natural killer defect in a patient with Chédiak-Higashi syndrome after bone-marrow transplantation. N Engl J Med 306: 1055–1056, 1982.Google Scholar
  168. 168.
    Stutman O, Figarella EF, Paige CJ, Lattime EC: Natural cytotoxic (NC) cells against solid tumors in mice: General characteristics and comparison to natural killer (NK) cells. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York, 1980, pp 187–229.Google Scholar
  169. 169.
    Kedar E, Ikejiri BL, Gorelik E, Herberman RB: Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell Growth Factor (TCGF). Cancer Immunol Immunother 13: 14–23, 1982.Google Scholar
  170. 170.
    Ault DA, Weiner HL: Natural killing of measles-infected cells by human lymphocytes. J Immunol 122: 2611–2616, 1979.Google Scholar
  171. 171.
    Bancroft GJ, Shellam GR, Chalmer JE: Genetic influences on the augmentation of natural killer (NK) cells during murine cytomegalovirus infection: Correlation with patterns of resistance. J Immunol 126: 988–994, 1981.Google Scholar
  172. 172.
    Lam KM, Linna TJ: Transfer of natural resistance to Marek's disease (JMV) with nonimmune spleen cells. II. Further characterization of protecting cell population. J Immunol 125: 715–718, 1980.Google Scholar
  173. 173.
    Welsh RM, Kiessling: Natural killer cell response to lymphocytic choriomeningitis virus in beige mice. Scand J Immunol 11: 363–367, 1980.Google Scholar
  174. 174.
    Haller O, Arnheiter H, Lindenmann J: Natural resistance of mice toward orthomyxoviruses. In: Herberman RB (ed) Natural cell-mediated immunity against tumors. Academic Press, New York, 1980, pp 1145–1161.Google Scholar
  175. 175.
    Cudkowicz G, Landy M, Shearer GM (eds): Natural resistance systems against foreign cells, tumors and microbes. Academic Press, New York, 1978.Google Scholar
  176. 176.
    Huh HD, Kim YB, Koren HS, Amos DB: Natural killing and antibody-dependent cellular cytotoxicity in specific-pathogen-free miniature swine and germ-free piglets. II. Ontogenic development of NK and ADCC. Int J Cancer 28: 175–178, 1981.Google Scholar
  177. 177.
    Murphy JW, McDaniel DO: In vitro reactivity of natural killer (NK) cells against cryptococcus neoformans. J Immunol 128: 1577–1583, 1982.Google Scholar
  178. 178.
    Smith PD, Elson CO, Keister DB, Nash TE: Human host response to giardia lamblia. I. Spontaneous killing by mononuclear leukocytes in vitro. J Immunol 128: 1372–1376, 1982.Google Scholar
  179. 179.
    Hatcher RM, KuHN RE, Cerrone C, Burton RC: Increased natural killer (NK) cell activity in experimental American trypanosomiasis. J Immunol 127: 1126–1130, 1981.Google Scholar
  180. 180.
    Attalah AM, Lewis FA, Urritia-Shaw A, Folks T, Yeatman TJ: Natural killer cells (NK) and antibody-dependent-cell-mediated cytotoxicity (ADCC) components of Schistosoma mansoni infection. Int Arch Allegry Appl Immunol 63: 351–354, 1980.Google Scholar
  181. 181.
    Oldham RK: Natural killer cells: History and significance. J Biol Resp Mod 1: 217–231, 1982.Google Scholar
  182. 182.
    Stutman O: NK cells, anti-tumor surveillance and interleukins. Immunol Today 2: 205–208, 1981.Google Scholar

Copyright information

© Martinus Nijhoff Publishers 1983

Authors and Affiliations

  • Robert K. Oldham
    • 1
  1. 1.Biological Response Modifiers Program, Division of Cancer TreatmentNCI-FCRFFrederickUSA

Personalised recommendations